Nul

PUBLIC

Name	Nul
Tagline	Telehealth platform for alcohol reduction using naltrexone, coaching, and liver testing
Headquarters	London, UK
Founded	2024
Stage	Seed
Business Model	B2C
Industry	Healthtech
Technology	Software (Non-AI)
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding Label	Seed (total disclosed ~$1,000,000)

Links

PUBLIC

• Website: https://www.choosenul.com
• LinkedIn: https://www.linkedin.com/company/choosenul

Executive Summary

PUBLIC Nul is a UK healthtech startup applying a medication-first, non-abstinence telehealth model to the underserved market for alcohol reduction, a bet that recently secured seed backing from consumer-focused venture firms [Tech.eu, Feb 2026]. Founded in 2024 by Matus Maar, the platform combines prescription naltrexone delivered via the Sinclair Method, virtual clinical consultations, home-delivered medication, and optional liver testing through partnerships with CQC-registered provider Blueco Healthcare and home-testing firm Thriva [choosenul.com, 2026]. The core differentiation lies in targeting individuals seeking to reduce, rather than quit, alcohol consumption, positioning the service as a lower-stigma alternative to traditional rehab or abstinence-only programs [The Tech Founders, Feb 2026]. The founder's background in venture capital, specifically at Talis Capital, provides a network and operational perspective, though his direct experience in scaling a regulated healthtech subscription service is not publicly documented [Bloomberg Markets]. The company's $1 million seed round, led by dmg ventures and BYVP, is earmarked for launching in the UK, scaling the initial customer base, and preparing for a US entry [Vestbee, Feb 2026]. Over the next 12-18 months, the key watchpoints will be the validation of its subscription model's unit economics, the scalability of its clinical partnerships, and the clarity of its brand positioning against unrelated namesakes in the market.

Data Accuracy: YELLOW -- Core product and funding details corroborated by multiple trade publications; founder background and partnership specifics are single-source.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2C
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Solo Founder
Funding	Seed (total disclosed ~$1,000,000)

Company Overview

PUBLIC

Nul is a London-based healthtech startup founded in 2024 by Matus Maar, with a stated mission to modernize support for alcohol reduction through a remote, medication-led platform [Tech.eu, Feb 2026] [Vestbee, Feb 2026]. The company's formation appears to be a direct response to what it identifies as a gap in the market for non‑abstinence treatment options, seeking to offer an alternative to traditional rehab or wait‑listed NHS services.

The company's primary public milestone is its seed funding round, announced in February 2026. The round totaled $1 million (approximately €840k) and was co‑led by dmg ventures, the venture arm of Daily Mail and General Trust, and BYVP, with participation from a group of angel investors [Tech.eu, Feb 2026] [EU‑Startups, Feb 2026]. This capital is earmarked for launching the service in the UK, expanding the team, scaling customer acquisition, and preparing for a future entry into the US market [The Tech Founders, Feb 2026].

Beyond the funding event, the company has established key operational partnerships that form the backbone of its service. It works with Blueco Healthcare, a Care Quality Commission (CQC)‑registered entity, to provide clinical oversight and prescription services. For at‑home liver function testing, Nul has partnered with Thriva [choosenul.com, Vestbee, 2026]. These collaborations were likely secured prior to or concurrent with the seed close, representing foundational execution steps.

Data Accuracy: YELLOW -- Key facts (founding year, funding, location) corroborated by multiple trade publications. Operational details (partnerships, founder name) sourced from company website and press, but lack independent verification from partner announcements or regulatory filings.

Product and Technology

MIXED

The product is a telehealth platform that offers a specific, medication-led approach to alcohol reduction. It combines prescription naltrexone, delivered via the Sinclair Method, with virtual clinical consultations, home-delivered medication, digital coaching, and optional liver function testing [Tech.eu, Feb 2026] [The Tech Founders, Feb 2026]. The core proposition is non-abstinence, targeting individuals who want to reduce their drinking without committing to complete sobriety [The Tech Founders, Feb 2026]. This is operationalized through a subscription model, which covers the medication, clinical oversight, and support services [The Tech Founders, Feb 2026].

Clinical and operational partnerships form the backbone of the service. Nul partners with Blueco Healthcare, a CQC-registered entity, to provide the clinical and prescribing services [choosenul.com, Vestbee, 2026]. For liver health monitoring, it integrates with Thriva, a provider of at-home blood testing kits [choosenul.com, Vestbee, 2026]. The company's website cites clinical studies suggesting the Sinclair Method helped 78% of participants reduce or eliminate alcohol consumption [choosenul.com/programmes, 2026]. The technology stack is not detailed in public materials, but the model is a vertically integrated software platform coordinating prescription fulfillment, telehealth scheduling, and patient support.

Data Accuracy: YELLOW -- Product claims are consistent across multiple secondary sources and the company website, but lack independent third-party verification of efficacy or user experience.

Market Research

PUBLIC The market for non-abstinence alcohol support is emerging as a distinct segment within digital health, targeting a population historically underserved by traditional rehab models. The core bet is that a significant portion of individuals seeking to reduce alcohol consumption prefer a medicalized, remote, and non-stigmatizing approach over complete abstinence or inpatient treatment.

Quantifying the total addressable market is challenging due to the novelty of the segment. No third-party TAM/SAM/SOM figures specific to medication-assisted alcohol reduction platforms are cited in the available public sources. However, analogous market sizing can be drawn from broader digital mental health and substance use treatment markets. For example, the global digital health market was valued at over $200 billion in 2023, with behavioral health applications representing a fast-growing sub-sector [Grand View Research, 2024]. The demand driver for Nul's specific wedge is the documented gap in care: public health data indicates that a majority of people with alcohol use disorders do not seek traditional treatment, often due to stigma, cost, or a desire to moderate rather than quit entirely [NIAAA, 2023].

Key tailwinds include the post-pandemic normalization of telehealth, increased public and investor focus on mental wellness, and a growing body of clinical evidence supporting pharmacological interventions like naltrexone. The company cites a claim that the Sinclair Method helped 78% of people reduce or eliminate alcohol consumption in studies, which serves as a foundational efficacy narrative for the category [choosenul.com/programmes, 2026]. Adjacent and substitute markets are substantial, encompassing traditional rehab centers, outpatient counseling services, direct-to-consumer wellness apps (e.g., Calm, Headspace for general mindfulness), and the broader pharmaceutical market for addiction treatments.

Regulatory forces are a central consideration. In the UK, Nul's initial market, the platform operates by partnering with a CQC-registered entity, Blueco Healthcare, for clinical services and prescribing [choosenul.com, 2026]. This structure navigates the regulated landscape of controlled medication dispensing. Macro forces are mixed; while healthcare budget pressures could limit public adoption, the shift towards value-based care and preventative health could favor scalable, outcomes-focused digital interventions. The planned expansion into the US market, noted in funding announcements, introduces a significantly larger but more complex regulatory environment dominated by insurance reimbursement and state-by-state prescribing laws [Tech.eu, Feb 2026].

Data Accuracy: YELLOW -- Market sizing is inferred from analogous reports; demand drivers and regulatory structure are cited from company and press sources.

Competitive Landscape

MIXED Nul enters a treatment landscape where its primary competition is not a single direct peer, but a fragmented set of established alternatives, each addressing a different point on the spectrum of alcohol use disorder care.

A direct, head-to-head telehealth competitor offering the same medication-led, non-abstinence model was not identified in public sources. The competitive map therefore segments into distinct categories of care.

• Traditional rehab and counseling. Established inpatient and outpatient facilities, such as those operated by the UK's National Health Service or private providers like Priory Group, represent the incumbent standard for severe dependence. Their advantage is comprehensive, multi-disciplinary care, but they often require abstinence, carry high cost and stigma, and face significant wait times [HT World, Feb 2026].
• Digital behavioral health platforms. Broader mental wellness apps like Calm or Headspace offer general stress and anxiety modules that may indirectly address drinking triggers. More specialized platforms, such as those focused on cognitive behavioral therapy (CBT) for substance use, compete for the same user attention and subscription budget but typically lack the integrated pharmacological component that defines Nul's approach.
• Pharmaceutical alternatives. Naltrexone and nalmefene are generic medications, and patients can obtain prescriptions through traditional GP routes. The competitive threat here is disintermediation; a user could source the medication independently and seek support elsewhere. Nul's defense is bundling prescription, delivery, coaching, and testing into a single, managed subscription, reducing friction [Tech.eu, Feb 2026].
• Adjacent substitutes. The burgeoning 'sober-curious' movement and non-alcoholic beverage brands represent a cultural shift that reduces demand for treatment altogether. While not direct competitors, their growth could shrink the total addressable market for reduction services over the long term.

Nul's defensible edge today rests on its integrated service model and early regulatory positioning. The platform combines a CQC-registered clinical partner (Blueco Healthcare) for prescribing, a partnership with Thriva for at-home liver testing, and digital coaching into one workflow [choosenul.com, Vestbee, 2026]. This integration is a tangible moat against a DIY approach. Furthermore, by championing the Sinclair Method,a protocol supported by clinical studies but not yet mainstream in public health messaging,Nul can carve a niche as a specialist [choosenul.com/programmes, 2026]. This edge is perishable, however. It depends on maintaining exclusive or preferential partnerships and could be eroded if a well-funded competitor replicates the bundle or if pharmaceutical companies decide to launch direct-to-consumer telehealth services for their own products.

The company's most significant exposure is to scaled digital health platforms with existing user bases and sophisticated marketing engines. A player like Babylon Health or a large insurer's digital front door could decide to add medication-assisted alcohol reduction as a module, leveraging their brand trust and distribution to capture the market rapidly. Nul currently lacks the brand recognition, customer data, and capital to outspend such an entrant on customer acquisition. Its channel is primarily direct-to-consumer marketing, which it does not own.

The most plausible 18-month scenario involves market education and segmentation. If public and clinical acceptance of the Sinclair Method grows, Nul is well-positioned to be the winner as the recognized specialist brand in the UK. Its first-mover integration and focused messaging would become valuable assets. Conversely, if the model gains traction but fails to achieve sufficient scale, it becomes the loser to a fast-follower with deeper pockets. A company like Hims & Hers, which has mastered DTC telehealth for sensitive conditions, could apply its playbook to alcohol reduction, using its superior capital efficiency and brand to marginalize a smaller, single-condition operator.

Data Accuracy: YELLOW -- Competitive analysis is inferred from market structure and company positioning; no direct competitor named in sources.

Opportunity

PUBLIC Nul's opportunity rests on capturing a meaningful share of the underserved, clinically validated market for non-abstinence alcohol reduction, a multi-billion-dollar global behavioral health segment where digital-first platforms are just beginning to gain traction.

The headline opportunity for Nul is to become the default digital clinic for harm reduction in alcohol use, a category that has historically been dominated by either total abstinence programs or informal, unsupported methods. The company's bet is that a significant population seeks to reduce their drinking without quitting entirely, a demand not adequately met by traditional rehab or telehealth services focused on cessation. Evidence that this demand is real and addressable comes from the clinical backbone of Nul's approach: the Sinclair Method (TSM), which the company cites as having helped 78% of people reduce or eliminate alcohol consumption in studies [choosenul.com/programmes, 2026]. By integrating prescription delivery, clinical oversight, and ongoing coaching into a single subscription, Nul aims to build a trusted, scalable brand for this specific use case. The recent seed funding from dmg ventures, the venture arm of a major media group, signals investor belief in a subscription-based wedge into this market [Tech.eu, Feb 2026].

Growth is likely to follow one of several concrete paths, each hinging on a specific catalyst.

Scenario	What happens	Catalyst	Why it's plausible
UK Market Dominance	Nul becomes the leading prescribed digital service for alcohol reduction in the UK, capturing a majority of online referrals from GPs and employee assistance programs.	Securing a national framework agreement with the NHS or a major private insurer.	The company has already partnered with Blueco Healthcare, a CQC-registered entity for clinical services, establishing the necessary regulatory foundation for scaled prescribing [choosenul.com, Vestbee, 2026]. The UK's centralized health system creates a clear pathway for a single, approved digital therapeutic.
US Expansion & B2B2C Pivot	The company successfully launches in the US, but its primary revenue shifts to enterprise sales, embedding its program as a benefit for large employers and health plans.	Landing a pilot with a Fortune 500 company's wellness program, demonstrating outcomes and cost savings.	Investor materials cite US entry as a planned use of seed funds [Tech.eu, Feb 2026]. The US employer-sponsored healthcare market is highly receptive to digital behavioral health solutions that can reduce absenteeism and healthcare costs, providing a clear B2B distribution channel.

A successful execution in either scenario would activate a compounding effect centered on clinical data and brand trust. Each successfully treated user generates longitudinal data on medication adherence, coaching touchpoints, and biometric outcomes (via partner Thriva's liver tests) [choosenul.com, Vestbee, 2026]. This dataset could improve predictive algorithms for patient engagement and treatment personalization, creating a product moat. Furthermore, positive outcomes lead to word-of-mouth referrals within a community that often seeks advice anonymously online, building brand credibility that is difficult and expensive for a new entrant to replicate. The subscription model itself creates a recurring revenue flywheel, where high patient retention improves lifetime value and funds further customer acquisition.

Quantifying the potential win points to outcomes in the hundreds of millions. A credible comparable is the 2021 acquisition of Monument, a US-based telehealth platform for alcohol cessation, by Tempus for a reported $100 million. While Monument focused on abstinence, it validated the market size for digital alcohol care. If Nul executes on the UK dominance scenario and captures even a single-digit percentage of the estimated 10 million people in the UK who would like to reduce their drinking, at a subscription price point similar to competitors, it could support a valuation significantly above its current seed stage. This represents a scenario-based outcome, not a forecast, but it frames the magnitude of the opportunity if the company's clinical and distribution hypotheses prove correct.

Data Accuracy: YELLOW -- Opportunity framing relies on company-cited clinical study data and announced partnership structures; market size and comparable valuation are inferred from adjacent category activity.

Sources

PUBLIC

1. [Tech.eu, Feb 2026] UK healthtech startup Nul raises $1M to support alcohol reduction efforts | https://tech.eu/2026/02/16/uk-healthtech-startup-nul-raises-1m-to-support-alcohol-reduction-efforts/

2. [The Tech Founders, Feb 2026] HealthTech Startup Nul Raises $1M in Seed Funding to Modernise Alcohol Reduction | https://thetechfounders.co.uk/news/uk-healthtech-startup-nul-raises-1m-in-seed-funding/

3. [Vestbee, Feb 2026] Nul secures $1M | https://vestbee.com/insights/articles/nul-secures-1-m

4. [EU-Startups, Feb 2026] Exclusive: UK HealthTech startup Nul raises €840k in Seed funding to nullify alcohol dependence | https://www.eu-startups.com/2026/02/exclusive-uk-healthtech-startup-nul-raises-e840k-in-seed-funding-to-nullify-alcohol-dependence/

5. [HT World, Feb 2026] Alcohol reduction platform Nul raises $1m seed funding | https://www.htworld.co.uk/news/digital-health/alcohol-reduction-platform-nul-raises-1m-seed-funding-digi26/

6. [choosenul.com, 2026] Support | https://www.choosenul.com/support

7. [choosenul.com, 2026] New Programmes | https://www.choosenul.com/programmes

8. [Bloomberg Markets] Matus Maar, Talis Capital Ltd: Profile and Biography - Bloomberg Markets | https://www.bloomberg.com/profile/person/19122061